Gilead's idelalisib gets standard FDA review
This article was originally published in Scrip
The FDA has granted a standard review to Gilead Sciences’ new drug application (NDA) to market idelalisib, a targeted oral phosphoinositide 3-kinase delta inhibitors, as a treatment for refractory indolent non-Hodgkin's lymphoma (iNHL), a group of largely incurable slow-growing lymphomas that run a relapsing course after therapy and lead ultimately to life-threatening complications, such as serious infections and marrow failure.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.